The stock has remained strong and is trading around its 52 week highs. Despite this, the P/E (ttm) is less than 22 and the forward P/E is significantly lower at 13.25 (fye Aug 2014) indicating expectations of growth. Though the business is having low margins of less than 3% (ttm), the price to sales of 0.66 appears to be attractive for a company of this size and brand strength. WAG is still trading at less than 2.5 times book. For the quarter ending Feb 28, 2013, the results were good as the margins expanded both on a YoY and QoQ basis. On YoY the revenues, however, remained flat at $18.647 billion for the quarter. Sequentially, the revenues increased around 7.6% and the margins expanded from 2.38% to 4.50%. The performance has added strength to the stocks performance, and its seems that new highs may be made in the near future. WAG had recently expanded services at its 370 in-store Take Care Clinics to diagnose, treat and monitor patients with chronic conditions like diabetes. Future growth is dependent on its association with manufacturers / developers who create great products. Smaller companies like ChromaDex Corporation (CDXC) have brought novel products recently. ChromaDex combined its successful proprietary ingredient pterostilbene with caffeine to create a molecule which gives same effects of caffeine at very low dosage. This avoids the harmful effects on high doses of caffeine in energy drinks. ChromaDex launched PURENERGY which is an energy drink containing that molecule. After launch of the product, investor Barry Honig increased his stake in the company indicating his confidence in the future. WAG has to bring in some novel concepts, and also keep the cost under control. Expansion of margins on such high volume of sales, leads to a lot of strengthening of the balance sheet. The future looks bright.